Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01490749 · ClinicalTrials.gov registry record · Phase 1
Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer
A Phase 1 study of Esophageal Cancer and Neoplasms, Esophageal, sponsored by Emory University.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
- 3
- Study locations
NCT01490749: Completed Phase 1 study of Esophageal Cancer and Neoplasms, Esophageal, sponsored by Emory University.
NCT01490749 is a Phase 1 study of Esophageal Cancer and Neoplasms, Esophageal that has completed, run by Emory University. The registered enrollment target is 17 participants, below the 499-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01490749, a Phase 1 study of Esophageal Cancer and Neoplasms, Esophageal, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to test the drug RAD001 in combination with another chemotherapy drug, Carboplatin, as well as radiation therapy in the treatment of esophageal cancer. Because RAD001 has not been used in this combination before, it is not clear which dose will be best when used in combination. The standard of care for patients who have esophageal cancer that has not moved to other areas of the body (non-metastatic) includes a combination of chemotherapy, radiation therapy and possibly surgery. If the patient chooses to participate in this study, the patient will receive chemotherapy and radiation therapy. The patient will possibly also have surgery to have the cancer removed. This decision will be made by the treating physicians. All of the chemotherapy the patient will receive on the study is considered standard chemotherapy for esophagus cancer. The investigators do not know as of yet if the drug called RAD001 will help improve the treatment for patients with this disease. RAD001 is a pill that has been used in many other types of cancer and has been proven to be effective in other cancers such as kidney cancer.
Conditions Studied
Interventions
- DRUG Carboplatin
- RADIATION Radiation
- DRUG XELOX
- DRUG RAD001
Study Locations (3)
Georgia
- Emory University Hospital Midtown - Atlanta
- Emory University Winship Cancer Institute - Atlanta
Tennessee
- Vanderbilt University - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2012-02 |
| Est. Completion | 2019-02 |
| Phase | Phase 1 |
What the finished NCT01490749 record still lists
NCT01490749 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 499-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Esophageal Cancer appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.
NCT01490749 reports a single indexed study location in Georgia, Tennessee.
Frequently Asked Questions
What is clinical trial NCT01490749 about?
NCT01490749 is a clinical study titled "Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer". The purpose of this study is to test the drug RAD001 in combination with another chemotherapy drug, Carboplatin, as well as radiation therapy in the treatment of esophageal cancer. Because RAD001 has not been used in this combination before, it is not clear which dose will be best when used in combi...
What is the current status of trial NCT01490749?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2012-02. Estimated completion is 2019-02.
What conditions does trial NCT01490749 study?
This clinical trial studies the following conditions: Esophageal Cancer, Neoplasms, Esophageal.
What interventions are being tested in trial NCT01490749?
The interventions under investigation include: Carboplatin (DRUG), Radiation (RADIATION), XELOX (DRUG), RAD001 (DRUG).
Who is sponsoring clinical trial NCT01490749?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01490749 being conducted?
This trial has 3 study locations across Georgia, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01490749's enrollment target sits among peer trials
17 113th of 123 higher than 11 of 123 other Esophageal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Esophageal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RECRUITING · Phase 1
-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia